Alkem Laboratories announced on Thursday that the US Food and Drug Administration had inspected its Taloja facility in Maharashtra and found “zero” issues.
From July 26-28, 2021, the US Food and Drug Administration (USFDA) conducted a remote and virtual bio-analytical inspection of Alkem Laboratories’ Bioequivalence Center in Taloja, Maharashtra, according to a regulatory filing.
At the end of the inspection, no form 483 was issued, the company added. A form 483 is issued by the USFDA to notify a company’s management of any objectionable condition at its manufacturing facility. The form is issued after completing the inspection.
Shares of Alkem Laboratories were trading 0.30 percent lower at Rs 3,362.05 apiece on BSE.
Uncovering the Molecular Secrets of Malaria’s Deadliest Strain: A New Research Project Malaria remains one…
Sunlight Can Cause Cancer: Prolonged exposure to sunlight and exposure to UV (ultraviolet) rays can…
https://youtu.be/mlBSCMO2NQg?si=UfC4C3WgtMZ9DhB4 Humans Are Swallowing Microplastics: A Hidden Environmental and Health Crisis In recent years, microplastics…
https://youtu.be/H_aiXVvX8Eg?si=vH4Arvq7pbpXERMF Obesity Drugs: A Comprehensive Guide to Weight Loss Solutions Obesity is one of the…
https://youtu.be/LZi8Jn0tAA8?si=bpMPudQxl1LUdgXN Cold Hands & Feet in Winter: Causes, Remedies, and Prevention Tips Winter can be…
Dysautonomia: The Silent Illness Impacting Millions of People Worldwide Dysautonomia is an umbrella term used…